Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Simon, Pauline" or (type exact bookEditor and editor="Simon, Pauline")

Add to list
Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)

Mattias Hofmans (UGent) , Stefan Suciu, Alina Ferster, Pieter Van Vlierberghe (UGent) , Françoise Mazingue, Nicolas Sirvent, Vitor Costa, Karima Yakouben, Catherine Paillard, Anne Uyttebroeck, et al.

(2019) BRITISH JOURNAL OF HAEMATOLOGY. 186(5). p.741-753
Add to list
Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials

Pauline Simon, Stefan Suciu, Emmanuelle Clappier, Hélène Cave, Nicolas Sirvent, Geneviève Plat, Antoine Thyss, Françoise Mechinaud, Vitor M Costa, Alina Ferster, et al.

(2016) ANNALS OF HEMATOLOGY. 95(1). p.93-103
Add to list
Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics

Gertjan JL Kaspers, Denise Niewerth, Bram Wilhelm, Satianand Ramnarain, Hans Berkhof, Valerie de Haas, Ron AA Mathôt, Andishe Attarbaschi, Andre Baruchel, Eveline S de Bont, et al.

(2015) BLOOD. 126(23).
Add to list
Results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed of refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ

Gertjan Kaspers, Denise Niewerth, Satianand Ramnarain, Andishe Attarbaschi, André Baruchel, Evelina S De Bont, Franca Fagioli, Barbara De Moerloose (UGent) , Karsten Nysom, Giuseppe Palumbo, et al.

(2014) BLOOD. 124(21).

Academic Bibliography

Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)

Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials

Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics

Results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed of refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ

Contents

Support

Contact